Intravitreal implant ILUVIEN, developed by Alimera Sciences, is now available in France, distributor Horus Pharma has announced.
ILUVIEN is aimed at patients with vision impairment associated with chronic Diabetic Macular Edema (DME), who have not responded well to other available therapies, such as laser photocoagulation or ranibizumab. In patients with chronic DME (≥3 years), ILUVIEN showed superiority over placebo after 24 months in terms of percentage of patients with an improved visual acuity of ≥15 letters.
DME is a type of diabetic retinopathy affecting the macula, the part of the retina responsible for central and fine vision. When DME occurs, the blood vessels in the retina swell and ooze, and the exuded fluid causes swelling of the macula. Macular edema then blurs vision and leads to long-term vision loss. DME is a serious condition that is becoming increasingly common and it is the leading cause of blindness among people under fifty.
“We are delighted about this successful cooperation with Alimera Sciences which enables us to market ILUVIEN in France for patients in need of a better alternative treatment for their DME,” said Martine Claret, President of Horus Pharma. “Horus Pharma, an independent ophthalmology laboratory, is a major player in Europe in innovative treatments for corneal conditions, in particular dry eye, wound healing, keratoconus and corneal edema. Distributing ILUVIEN® in France will allow Horus Pharma to broaden its therapeutic range in retinal diseases.”
Horus Pharma is an independent ophthalmology laboratory specializing in developing and marketing preservative-free health products for eyes and eyelids. It has a portfolio of over fifty innovative products for ophthalmology, dermo-ophthalmology, contactology ocular micronutrition as well as surgery.